Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Income from Continuing Operations (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Income from Continuing Operations for 12 consecutive years, with 23283000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 53.7% year-over-year to 23283000.0; the TTM value through Mar 2026 reached 160077000.0, down 314.59%, while the annual FY2025 figure was 153942000.0, 293.67% down from the prior year.
  • Income from Continuing Operations hit 23283000.0 in Q1 2026 for Crescent Biopharma, up from 90397000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2631000.0 in Q3 2024 and bottomed at 90397000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 17642268.44, with a median of 10548008.5 recorded in 2023.
  • Year-over-year, Income from Continuing Operations surged 71.41% in 2024 and then tumbled 835.27% in 2025.
  • Crescent Biopharma's Income from Continuing Operations stood at 10244355.0 in 2022, then rose by 11.38% to 9078640.0 in 2023, then soared by 71.02% to 2631000.0 in 2024, then plummeted by 3335.84% to 90397000.0 in 2025, then skyrocketed by 74.24% to 23283000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 23283000.0, 90397000.0, and 24607000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.